Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones April 25, 2025 CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 - Read More January 9, 2025 CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab - Read More December 11, 2024 CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature - Read More Load MoreLoadingMeet us at the following conferences & events J.P. Morgan Healthcare Conference 2025 Jan 13 - Jan 16, 2025 San Francisco, USA Read More
